Icosapent Ethyl
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Icosapent Ethyl: From Undocumented Original Indication to Hemoglobinopathy
One-Sentence Summary
Icosapent ethyl (DB08887) has no original indication or licensing record in the current evidence pack, and the drug is marked as not marketed in this jurisdiction. The TxGNN model predicts potential efficacy for Hemoglobinopathy, but this direction is currently supported by only 1 preclinical publication (studying a structurally related compound, not icosapent ethyl itself) and no clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented — no license record found in evidence pack |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.09% |
| Evidence Level | L5 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not on file (flagged as a High-severity data gap, DG002). Based on available rationale data, icosapent ethyl is a purified ethyl ester of EPA (eicosapentaenoic acid), with known pharmacologic effects including anti-inflammatory activity, antithrombotic activity, red blood cell membrane lipid stabilization, and antioxidant activity.
The only supporting literature discusses epeleuton, a synthetic ω-3 fatty acid analog — not icosapent ethyl itself — which reduced hypoxia/reperfusion stress in a mouse model of sickle cell disease (a hemoglobinopathy). The theoretical link is that EPA-class compounds stabilize red blood cell membranes and reduce oxidative stress, which is mechanistically plausible for hemoglobinopathy pathophysiology (membrane fragility, vaso-occlusion, hypoxia/reperfusion injury). However, this is an analogical extrapolation from a structurally related molecule, not direct evidence on icosapent ethyl, and should be weighted accordingly.
Because no original indication is documented for icosapent ethyl in this evidence pack, a direct comparison between original and new indication cannot be made at this time (similarity assessment marked “pending”).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38105727 | 2024 | Animal Model (Preclinical) | Haematologica | Epeleuton, a synthetic ω-3 fatty acid analog (structurally related to icosapent ethyl but not the same compound), reduced hypoxia/reperfusion-induced inflammatory vasculopathy in a mouse model of sickle cell disease. |
US Market Information
No licenses on file. The evidence pack indicates the drug is not marketed (未上市) in this jurisdiction, with 0 total license records.
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA label warnings/contraindications are flagged as a Blocking data gap (DG001) — safety data must be obtained before this candidate can enter initial safety screening (S1).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 (model prediction only) — the sole supporting publication studies a related but distinct compound (epeleuton) in an animal model, not icosapent ethyl in humans, and no clinical trials exist for this drug-disease pair.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, Blocking) — required before S1 safety screening
- Confirmed mechanism of action for icosapent ethyl itself (DG002, High priority)
- Direct preclinical or clinical evidence for icosapent ethyl (not the analog epeleuton) in hemoglobinopathy models
- Clarification of original approved indication and licensing status, since none is currently on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.